Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
1.300
+0.030 (2.36%)
At close: Aug 13, 2025, 4:00 PM
1.240
-0.060 (-4.61%)
Pre-market: Aug 14, 2025, 9:07 AM EDT
Hoth Therapeutics Employees
As of December 31, 2024, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,335,640
Market Cap
17.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HOTH News
- 16 days ago - Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe - PRNewsWire
- 23 days ago - Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins - PRNewsWire
- 7 weeks ago - Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. - PRNewsWire
- 7 weeks ago - Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects - PRNewsWire
- 7 weeks ago - Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy - PRNewsWire
- 2 months ago - Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth - PRNewsWire
- 2 months ago - Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway - PRNewsWire
- 2 months ago - Hoth Therapeutics to Attend 2025 BIO International Convention - PRNewsWire